Browse the evidence

GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.

If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.

Endoscopic Bariatric Procedures (EBP), including intragastric balloon (IGB), aspiration therapy (AT), and primary obesity surgery endoluminal (POSE), are generally less effective than newer OMMs (semaglutide, tirzepatide) and have limited long-term data.

Endoscopic procedures (IGB, AT, POSE, ESG) offer moderate weight loss (3.8-12.8% TBWL) in the short term but are generally less effective than newer medications (semaglutide, tirzepatide) and lack long-term efficacy data. They may be considered for patients who are not candidates for surgery or high-dose medications, but they are not the most effective option for significant, sustained weight loss.

Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.

This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).

High vegetable intake is inversely associated with cardiovascular disease (CVD) mortality in Japanese women, but this association is not observed in men.

For Japanese women, increasing vegetable intake is associated with a lower risk of dying from heart disease. For men in this specific population, no such link was found. This suggests that while vegetables are generally healthy, their protective effect against heart disease mortality may be sex-dependent.

Phentermine and Phentermine/Topiramate are associated with a higher incidence of acute kidney injury (AKI) and kidney injury events compared to other anti-obesity medications, and require dose adjustments in CKD stages 3+.

Avoid stimulant-based weight loss drugs like phentermine if you have CKD, especially stage 3 or higher. They carry a higher risk of kidney injury and require dose adjustments. GLP-1 medications are a safer and more effective option for protecting your kidneys while losing weight.

Orlistat use in CKD patients is associated with a risk of acute kidney injury (AKI) or end-stage renal disease (ESRD) due to oxalate nephropathy, requiring monitoring of urinary oxalate.

If you have CKD, be cautious with Orlistat. It can increase oxalate levels in your urine, which may lead to kidney stones or kidney injury (AKI/ESRD). Monitor your kidney function closely if you use it, and discuss safer alternatives like GLP-1 agonists with your doctor.

Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.

If GLP-1 mono-agonists (like semaglutide) are not enough, dual agonists (like cotadutide or pemvidutide) may offer greater liver fat reduction and fibrosis improvement. However, these drugs are more complex and may cause more side effects. They are currently in clinical trials and not yet standard care. Discuss with your hepatologist if you are a candidate for these newer agents, especially if you have significant liver fat but stable diabetes.

Semaglutide use is associated with a high incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with signal strength varying by clinical priority and time-to-onset.

If you are taking semaglutide, expect gastrointestinal side effects like nausea, vomiting, or diarrhea, especially when starting or increasing the dose. These are common and often decrease over time. Discuss starting with a lower dose and titrating slowly with your provider to improve tolerance. Ensure you stay hydrated and eat smaller, bland meals if symptoms occur.

Brown adipose tissue (BAT) activation and 'browning' of white adipose tissue represent a potential therapeutic target for increasing energy expenditure and reducing body weight.

Activating brown fat through cold exposure or potentially future medications may help burn more calories. However, this is still an area of active research, and current approved treatments focus more on hormonal regulation.

Aspartame and other non-nutritive sweeteners (NNS) do not promote weight gain, contrary to common belief that they stimulate appetite or cause metabolic harm.

If you use aspartame, don't worry about it causing weight gain. It does not appear to trigger the compensatory eating that some fear.

Gut microbiota dysbiosis in obesity contributes to low-grade inflammation and increased fat storage through mechanisms including increased gut permeability (leaky gut), systemic lipopolysaccharide (LPS) circulation, and altered signaling of satiety hormones (GLP-1, PYY, ghrelin) via the gut-brain axis.

Focus on dietary fiber and diverse plant foods to support a healthy gut microbiome, which may help regulate satiety hormones and reduce inflammation. While not a standalone cure, this biological lever supports overall metabolic health.

Short-chain fatty acids (SCFAs) produced by gut microbiota from dietary fiber can influence satiety, energy expenditure, and glucose metabolism, but human trials on oral SCFA supplementation have shown mixed or null results for improving glucose metabolism or vagal tone.

Prioritize dietary fiber intake to naturally produce SCFAs in the gut, rather than relying on oral SCFA supplements, which have not consistently shown benefits in human trials.

Six months of once-weekly GLP-1 analogue (semaglutide) therapy restores natural killer (NK) cell effector function (cytotoxicity and cytokine production) in people with obesity, independent of weight loss.

For people with obesity, GLP-1 therapy (like semaglutide) may strengthen the immune system's ability to fight viruses and cancer, independent of how much weight is lost. This suggests benefits beyond just metabolic health.

GLP-1 therapy restores NK cell metabolism by upregulating the CD98-mTOR-glycolysis axis, which is critical for NK cell cytokine production.

GLP-1 therapy helps fix the 'metabolic engine' of immune cells (NK cells) in obese individuals, allowing them to produce necessary defense chemicals (cytokines) more effectively.

Cholecystokinin (CCK) attenuates reward-related signaling and motivation for food, acting as a satiety signal that can block the acquisition of conditioned place preference associated with rewarding stimuli.

Satiety hormones like CCK don't just turn off hunger; they can also reduce the reward value of food, making it less appealing.

In adults with type 2 diabetes, weight gain is associated with a significantly increased risk of cardiovascular disease events and all-cause mortality, whereas intentional behavioral weight loss interventions have not demonstrated a statistically significant reduction in CVD events.

For adults with type 2 diabetes, gaining weight is clearly linked to higher risks of heart disease and death. However, simply trying to lose weight through diet and exercise has not been proven to reduce the risk of cardiovascular events in this population, according to this review. Patients should focus on overall cardiovascular risk management rather than assuming weight loss alone protects the heart.

Large-scale precision nutrition interventions targeting individual behavioral modification are unlikely to reduce obesity at a population level because they ignore the structural and environmental causes of incidence.

Do not rely solely on personalized diet apps or genetic testing to solve obesity. These tools focus on individual behavior, which is heavily constrained by your environment (food availability, cost, marketing). To effectively manage weight, you must combine personalized advice with structural changes to your environment, such as advocating for policy changes or modifying your immediate food access, rather than expecting data-driven advice alone to overcome an obesogenic environment.

Large-scale precision nutrition interventions are likely to exacerbate socioeconomic inequalities in obesity because socially privileged groups are more likely to adopt and benefit from these interventions.

Be aware that personalized health advice often works best for those with higher socioeconomic status. If you are from a lower socioeconomic background, personalized advice alone may not be enough due to structural barriers like cost and access. Advocate for policies that make healthy choices easier and cheaper for everyone, rather than relying solely on individualized digital interventions.

GLP-1 receptor agonists should be discontinued prior to metabolic bariatric surgery to prevent delayed gastric emptying and aspiration pneumonia during anesthesia.

If you take GLP-1 medications (like Ozempic or Saxenda) and are having bariatric surgery, you MUST stop them before the procedure. Daily users should stop on the day of surgery; weekly users should stop one week prior. This prevents life-threatening aspiration pneumonia.

High-volume and high-intensity exercise may increase the risk of atrial fibrillation (AF) in athletes, suggesting a J-shaped relationship between exercise volume and AF risk.

While exercise is crucial for heart health, extremely high volumes of intense exercise may increase the risk of atrial fibrillation in athletes. Aim for moderate-volume exercise (5-20 MET hours/week) for optimal protection against AF.

Strict glycemic control is the only intervention proven to prevent or delay the development of diabetic neuropathy in patients with type 2 diabetes.

If you have Type 2 Diabetes, keeping your blood sugar strictly under control is the most important thing you can do to prevent nerve damage (neuropathy). While other drugs and lifestyle changes are used, strict glucose management is the only proven way to stop or slow this specific complication. Regular foot checks and patient education are also critical to catch issues early.

Increased oxidative stress (ROS) and mitochondrial dysfunction are early markers of weight gain, potentially preceding other metabolic changes.

Be aware that long-term weight gain, especially from high-fat/sucrose diets, may increase oxidative stress and mitochondrial dysfunction, which can further promote weight gain. Addressing these underlying metabolic issues may be key to breaking the cycle.

Manipulations of resistance training variables (such as volume, intensity, or frequency) have a negligible impact on muscle fiber hypertrophy compared to intrinsic biological factors.

Stop obsessing over perfecting your set and rep schemes. Your genetic and biological response to training is the main driver of muscle growth, not whether you do 8 reps or 12. Focus on consistent, hard training and recovery rather than constantly changing variables.

Adipose-derived mesenchymal stem cell (ADMSC) therapy reduces body weight and improves metabolic complications (diabetes, NAFLD) in animal models, though clinical efficacy remains controversial due to low cell survival rates.

ADMSC therapy shows promise in reducing weight and improving metabolic health in animal studies, but it is not yet a standard or proven treatment for humans. Clinical efficacy is controversial, and cell survival after transplantation is low. Patients should not expect this to be a current standard of care.